What is the main purpose of the latest capital raising by Radiopharm Theranostics (ASX:RAD)?

Radiopharm Theranostics (ASX:RAD) raised funds primarily to prepare for its RAD101 Phase 3 clinical trial. The company stated that the capital will also support the RAD 204 dose escalation and advance the RAD 402 and RV01 therapeutic programmes.

How much capital did Radiopharm Theranostics (ASX:RAD) raise from institutional investors?

Radiopharm Theranostics (ASX:RAD) secured $12.5 million through an institutional placement and concurrent US direct offering. This includes an $6.7 million placement to Australian and international institutional investors alongside a US$4.1 million direct registered offering.

What are the key financial terms for new shares issued by Radiopharm Theranostics (ASX:RAD)?

Radiopharm Theranostics (ASX:RAD) set the Australian placement offer price at $0.015 per new share. The US direct offering was priced at US$3.16 per American Depositary Share.

How can existing shareholders participate in the Radiopharm Theranostics (ASX:RAD) capital plan?

Radiopharm Theranostics (ASX:RAD) launched a Share Purchase Plan aiming to raise up to an additional $6 million from eligible shareholders. Participating shareholders can apply for up to $100,000 worth of new shares at $0.015 per share or at a 2.5% discount to the five-day volume-weighted average price.

What attachable options or warrants are provided to Radiopharm Theranostics (ASX:RAD) subscribers?

Radiopharm Theranostics (ASX:RAD) is offering subscribers one free attaching option for every new share, exercisable at $0.018 until July 31, 2029, subject to shareholder approval. US subscribers will receive one warrant per ADS purchased under the direct offering.

Health

Image for illustrative purposes only. Not a real photo.

Radiopharm Theranostics raises $12.5M in placement

Written by Mahathir BayenaPublished Jul 26, 2026, 10:30 PM

· Radiopharm Theranostics secured $12.5 million via an institutional placement and US direct offering.

· New shares were priced at $0.015 each, representing a 21.1% discount to the previous closing price.

· Proceeds will fund preparation for the RAD101 Phase 3 trial and support clinical oncology pipelines.

Radiopharm Theranostics (ASX:RAD) secured $12.5 million in fresh capital through an institutional raising.

The new shares were offered at $0.015 each, representing a 21.1% discount to the previous close.

“We are grateful for the strong support shown by investors,” said Radiopharm Theranostics Managing Director Riccardo Canevari.

The raising includes a US$6 million share purchase plan.

Following the announcement, the Radiopharm Theranostics share price was unchanged at $0.02.

The company specialises in developing targeted radiopharmaceutical therapies for oncology applications with high unmet needs.

Proceeds will fund readiness for the RAD101 Phase 3 study and advance additional clinical programmes.

Radiopharm Theranostics raises $12.5M in placement

Perguntas frequentes

Ativos relacionados a notícia